The rational basis for the possible utility of PDE4 inhibitors in RA is the evidence that the c-AMP increase in leukocytes is associated with the block of several leukocyte functions, including TNF-α production and the subsequent release of other inflammatory mediators and reactive oxygen species [136]. This evidence concerns the gene TNF and rheumatoid arthritis.